Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials

[1] Nauck MA(2017)Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors Circulation 136 849-70

[2] Meier JJ(2018)Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis Lancet Diabetes Endocrinol 6 105-113

[3] Cavender MA(2021)GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs Cardiovasc Diabetol 20 189-737

[4] Abd El Aziz M(2017)Differential effects of glucagon-like peptide-1 receptor agonists on heart rate Cardiovasc Diabetol 16 6-37

[5] Drucker DJ(2014)Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus Hypertension 64 731-1529

[6] Bethel MA(2015)Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis Diabetes Res Clin Pract 110 26-130

[7] Patel RA(2018)Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Lancet 392 1519-322

[8] Merrill P(2019)Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Lancet 394 121-2257

[9] Lokhnygina Y(2016)Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 375 311-851

[10] Buse JB(2015)Lixisenatide in patients with type 2 diabetes and acute coronary syndrome N Engl J Med 373 2247-1844

[1] Nauck MA(2017)Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors Circulation 136 849-70

[2] Meier JJ(2018)Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis Lancet Diabetes Endocrinol 6 105-113

[3] Cavender MA(2021)GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs Cardiovasc Diabetol 20 189-737

[4] Abd El Aziz M(2017)Differential effects of glucagon-like peptide-1 receptor agonists on heart rate Cardiovasc Diabetol 16 6-37

[5] Drucker DJ(2014)Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus Hypertension 64 731-1529

[6] Bethel MA(2015)Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis Diabetes Res Clin Pract 110 26-130

[7] Patel RA(2018)Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Lancet 392 1519-322

[8] Merrill P(2019)Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Lancet 394 121-2257

[9] Lokhnygina Y(2016)Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 375 311-851

[10] Buse JB(2015)Lixisenatide in patients with type 2 diabetes and acute coronary syndrome N Engl J Med 373 2247-1844